Latest & greatest articles for copd

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on copd or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on copd and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for copd

161. Exercise programs after pulmonary rehabilitation for patients with chronic obstructive pulmonary disease (COPD): a rapid review

Exercise programs after pulmonary rehabilitation for patients with chronic obstructive pulmonary disease (COPD): a rapid review Exercise programs after pulmonary rehabilitation for patients with chronic obstructive pulmonary disease (COPD): a rapid review Exercise programs after pulmonary rehabilitation for patients with chronic obstructive pulmonary disease (COPD): a rapid review Health Quality Ontario Record Status This is a bibliographic record of a published health technology assessment (...) from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Health Quality Ontario. Exercise programs after pulmonary rehabilitation for patients with chronic obstructive pulmonary disease (COPD): a rapid review. Toronto: Health Quality Ontario (HQO). Rapid Review. 2015 Authors' conclusions There was no evidence found on exercise programs for pneumonia patients. Despite some methodological flaws, based on 1 meta-analysis of 6 randomized

Health Technology Assessment (HTA) Database.2015

162. Prophylactic antibiotics for individuals with Chronic Obstructive Pulmonary Disease (COPD): a rapid review

Prophylactic antibiotics for individuals with Chronic Obstructive Pulmonary Disease (COPD): a rapid review Prophylactic antibiotics for individuals with Chronic Obstructive Pulmonary Disease (COPD): a rapid review Prophylactic antibiotics for individuals with Chronic Obstructive Pulmonary Disease (COPD): a rapid review Health Quality Ontario Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality (...) of this assessment has been made for the HTA database. Citation Health Quality Ontario. Prophylactic antibiotics for individuals with Chronic Obstructive Pulmonary Disease (COPD): a rapid review. Toronto: Health Quality Ontario (HQO). Rapid Review. 2015 Authors' conclusions The evidence yielded mixed results on the effectiveness and safety of the prophylactic use of the antibiotic azithromycin (AZM) for COPD patients. From the examination of 1 systematic review of RCTs (in Rapid Review, proper): Compared

Health Technology Assessment (HTA) Database.2015

163. Respiratory therapy services in home care for individuals with chronic obstructive pulmonary disease (COPD): a rapid review

Respiratory therapy services in home care for individuals with chronic obstructive pulmonary disease (COPD): a rapid review Respiratory therapy services in home care for individuals with chronic obstructive pulmonary disease (COPD): a rapid review Respiratory therapy services in home care for individuals with chronic obstructive pulmonary disease (COPD): a rapid review Health Quality Ontario Record Status This is a bibliographic record of a published health technology assessment from a member (...) of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Health Quality Ontario. Respiratory therapy services in home care for individuals with chronic obstructive pulmonary disease (COPD): a rapid review. Toronto: Health Quality Ontario (HQO). Rapid Review. 2015 Authors' conclusions There were no studies that reported the effect of RT services on the time interval between acute exacerbations. Based on the results of a very small RCT with serious

Health Technology Assessment (HTA) Database.2015

164. Airway clearance techniques for patients with stable chronic obstructive pulmonary disease (COPD): a rapid review

Airway clearance techniques for patients with stable chronic obstructive pulmonary disease (COPD): a rapid review Airway clearance techniques for patients with stable chronic obstructive pulmonary disease (COPD): a rapid review Airway clearance techniques for patients with stable chronic obstructive pulmonary disease (COPD): a rapid review Wang M Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality (...) of this assessment has been made for the HTA database. Citation Wang M. Airway clearance techniques for patients with stable chronic obstructive pulmonary disease (COPD): a rapid review. Toronto: Health Quality Ontario (HQO). Rapid Review. 2015 Authors' conclusions One systematic review was included that examined airway clearance techniques for patients with stable COPD. The 19 studies (4 of which were only available as abstracts) were generally of low quality, based on risk of bias assessment; due

Health Technology Assessment (HTA) Database.2015

165. Self-care support for people with COPD

Self-care support for people with COPD This evidence briefing has been produced by the Centre for Reviews and Dissemination. Full details of methods are available on request (paul.wilson@ york.ac.uk or liz.bickerdike@york.ac.uk). The content of this briefing was judged to be up to date as of June 2014. The briefing has been produced as part of independent research funded by the NIHR Health Services and Delivery Research programme (Project ref: 12/5002/18). The views expressed (...) in this publication are those of the authors and do not necessarily reflect those of the NIHR or the Department of Health. • As the prevalence of long-term conditions increases there is a greater focus on encouraging people to manage their condition(s). • Self-care has been identified as integral to maintaining the health and wellbeing of people with COPD. • There is consistent evidence that multicomponent interventions reduce respiratory-related hospital admissions and improve quality of life for people

Evidence briefings2015

166. Lung cancer in patients with chronic obstructive pulmonary disease. Development and validation of the COPD Lung Cancer Screening Score

Lung cancer in patients with chronic obstructive pulmonary disease. Development and validation of the COPD Lung Cancer Screening Score 25522175 2015 01 31 2015 04 20 2017 02 20 1535-4970 191 3 2015 Feb 01 American journal of respiratory and critical care medicine Am. J. Respir. Crit. Care Med. Lung cancer in patients with chronic obstructive pulmonary disease. Development and validation of the COPD Lung Cancer Screening Score. 285-91 10.1164/rccm.201407-1210OC Patients (...) with chronic obstructive pulmonary disease (COPD) are at high risk for lung cancer (LC) and represent a potential target to improve the diagnostic yield of screening programs. To develop a predictive score for LC risk for patients with COPD. The Pamplona International Early Lung Cancer Detection Program (P-IELCAP) and the Pittsburgh Lung Screening Study (PLuSS) databases were analyzed. Only patients with COPD on spirometry were included. By logistic regression we determined which factors were independently associated with LC in PLuSS

EvidenceUpdates2015 Full Text: Link to full Text with Trip Pro

167. Efficacy and safety of once-daily QVA149 compared with the free combination of once-daily tiotropium plus twice-daily formoterol in patients with moderate-to-severe COPD (QUANTIFY): a randomised, non-inferiority study

Efficacy and safety of once-daily QVA149 compared with the free combination of once-daily tiotropium plus twice-daily formoterol in patients with moderate-to-severe COPD (QUANTIFY): a randomised, non-inferiority study 25677679 2015 03 13 2015 06 09 2015 11 19 1468-3296 70 4 2015 Apr Thorax Thorax Efficacy and safety of once-daily QVA149 compared with the free combination of once-daily tiotropium plus twice-daily formoterol in patients with moderate-to-severe COPD (QUANTIFY): a randomised, non (...) -inferiority study. 311-9 10.1136/thoraxjnl-2014-206345 QVA149 is a once-daily (o.d.) inhaled dual bronchodilator containing a fixed-dose combination of the long-acting β2-agonist indacaterol and the long-acting muscarinic antagonist glycopyrronium for the treatment of COPD. The QUANTIFY study compared QVA149 with a free-dose bronchodilator combination of tiotropium plus formoterol (TIO+FOR) in improving health-related quality of life (HRQoL) of patients with COPD. This multicentre, blinded, triple-dummy

EvidenceUpdates2015 Full Text: Link to full Text with Trip Pro

168. In patients presenting with an exacerbation of COPD can a normal venous blood gas pCO2 rule out arterial hypercarbia?

In patients presenting with an exacerbation of COPD can a normal venous blood gas pCO2 rule out arterial hypercarbia? BestBets: In patients presenting with an exacerbation of COPD can a normal venous blood gas pCO2 rule out arterial hypercarbia? In patients presenting with an exacerbation of COPD can a normal venous blood gas pCO2 rule out arterial hypercarbia? Report By: Mark Woods - Consultant in Emergency Medicine Search checked by David Hodgson - ST5 Emergency Medicine Institution: Whiston (...) Hospital, Merseyside, UK and Mersey School of Emergency Medicine, UK Date Submitted: 31st August 2012 Date Completed: 10th March 2015 Last Modified: 11th March 2015 Status: Green (complete) Three Part Question In [patients with an Acute Exacerbation of COPD] can a [normal venous blood gas CO2] [rule out arterial hypercarbia]? Clinical Scenario A 74 year old male patient with known COPD presents acutely breathless with widespread wheeze. He refuses an arterial blood gas (ABG) and complains that last

BestBETS2015

169. Umeclidinium/vilanterol (as trifenatate) (Anoro Ellipta) - chronic obstructive pulmonary disease (COPD)

Umeclidinium/vilanterol (as trifenatate) (Anoro Ellipta) - chronic obstructive pulmonary disease (COPD) Final Appraisal Recommendation Advice No: 0215 – February 2015 Umeclidinium/vilanterol (as trifenatate) (Anoro ® Ellipta ® ? ) 55 micrograms/22 micrograms inhalation powder Submission by GlaxoSmithKline UK In reaching the above recommendation AWMSG has taken account of the appraisal documentation prepared by the AWMSG Secretariat (reference number 1038), which includes the AWMSG Secretariat (...) to relieve symptoms in adult patients with chronic obstructive pulmonary disease (COPD).

All Wales Medicines Strategy Group2015

170. Global Strategy for Diagnosis, Management, and Prevention of COPD

Global Strategy for Diagnosis, Management, and Prevention of COPD ');//--> Search Menu Connect With Us Search in: Title 25 Broadway New York, NY 10004 (212) 315-8600 ATS Journals Services General Information Copyright © 1987-2017 American Thoracic Society, All Rights Reserved.

European Respiratory Society2015

171. Mortality risk prediction in COPD by a prognostic biomarker panel

Mortality risk prediction in COPD by a prognostic biomarker panel 25034566 2014 12 01 2015 07 20 2015 11 19 1399-3003 44 6 2014 Dec The European respiratory journal Eur. Respir. J. Mortality risk prediction in COPD by a prognostic biomarker panel. 1557-70 10.1183/09031936.00043814 Chronic obstructive pulmonary disease (COPD) is a complex disease with various phenotypes. The simultaneous determination of multiple biomarkers reflecting different pathobiological pathways could be useful (...) in identifying individuals with an increased risk of death. We derived and validated a combination of three biomarkers (adrenomedullin, arginine vasopressin and atrial natriuretic peptide), assessed in plasma samples of 385 patients, to estimate mortality risk in stable COPD. Biomarkers were analysed in combination and defined as high or low. In the derivation cohort (n = 142), there were 73 deaths during the 5-year follow-up. Crude hazard ratios for mortality were 3.0 (95% CI 1.8-5.1) for one high biomarker

EvidenceUpdates2015 Full Text: Link to full Text with Trip Pro

172. Prevention of Acute Exacerbations of COPD

Prevention of Acute Exacerbations of COPD 894 Evidence-Based Medicine [ 147#4 CHEST APRIL 2015 ] P r e v en tio n o f A c u t e Exacerba tio n s o f C O PD American College of Chest Physicians and Canadian Th oracic Society Guideline Gerard J. Criner , MD, FCCP ; Jean Bourbeau , MD, FCCP ; Rebecca L. Diekemper , MPH ; Daniel R. Ouellette , MD, FCCP ; Donna Goodridge , RN, PhD ; Paul Hernandez , MDCM ; Kristen Curren , MA ; Meyer S. Balter , MD, FCCP ; Mohit Bhutani , MD, FCCP ; Pat G. Camp (...) , PhD, PT ; Bartolome R. Celli , MD, FCCP ; Gail Dechman , PhD, PT ; Mark T. Drans? eld , MD ; Stanley B. Fiel , MD, FCCP ; Marilyn G. Foreman , MD, FCCP ; Nicola A. Hanania , MD, FCCP ; Belinda K. Ireland , MD ; Nathaniel Marchetti , DO, FCCP ; Darcy D. Marciniuk , MD, FCCP ; Richard A. Mularski , MD, MSHS, MCR, FCCP ; Joseph Ornelas , MS ; Jeremy D. Road , MD ; and Michael K. Stickland , PhD BACKGROUND: COPD is a major cause of morbidity and mortality in the United States as well as throughout

American College of Chest Physicians2015

173. Executive Summary: Prevention of Acute Exacerbation of COPD

Executive Summary: Prevention of Acute Exacerbation of COPD 883 journal.publications.chestnet.org E x e c u t i v e S umm a r y Prevention of Acute Exacerbation of COPD: American College of Chest Physicians and Canadian Th oracic Society Guideline Gerard J. Criner , MD, FCCP ; Jean Bourbeau , MD, FCCP ; Rebecca L. Diekemper , MPH ; Daniel R. Ouellette , MD, FCCP ; Donna Goodridge , RN, PhD ; Paul Hernandez , MDCM ; Kristen Curren , MA ; Meyer S. Balter , MD, FCCP ; Mohit Bhutani , MD, FCCP (...) - 893 ABBREVIATIONS : AEC O P D 5 ac u t e exacerba tio n o f C O PD ; C D C 5 US C en t er s f o r Dis e as e C o n t r o l a n d P r e v en tio n ; CHES T 5 Amer ica n C o lleg e o f Chest Ph ysicia n s ; CT S 5 Canadian Th oracic S o ciety ; WH O 5 W o r l d H e a l t h Or ga niza tio n COPD is a common disease with substantial associated morbidity and mortality. Patients with COPD usually have a progression of airfl ow obstruction that is not fully reversible and can lead to a history of progres

American College of Chest Physicians2015

174. Randomised controlled trial: Discontinuing inhaled steroids might not be safe in severe COPD cases

Randomised controlled trial: Discontinuing inhaled steroids might not be safe in severe COPD cases Discontinuing inhaled steroids might not be safe in severe COPD cases | Evidence-Based Medicine This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu (...) Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Discontinuing inhaled steroids might not be safe in severe COPD cases Article Text Therapeutics/Prevention Randomised controlled trial Discontinuing inhaled steroids might not be safe in severe COPD cases Rafael Laniado-Laborín Statistics from Altmetric.com No Altmetric data available for this article. Commentary on : Magnussen H , Disse

Evidence-Based Medicine (Requires free registration)2015

175. Pulmonary Rehabilitation for Postacute Exacerbations of Chronic Obstructive Pulmonary Disease (COPD): A Cost-Effectiveness and Budget Impact Analysis

Pulmonary Rehabilitation for Postacute Exacerbations of Chronic Obstructive Pulmonary Disease (COPD): A Cost-Effectiveness and Budget Impact Analysis Pulmonary Rehabilitation for Postacute Exacerbations of Chronic Obstructive Pulmonary Disease (COPD): A Cost-Effectiveness and Budget Impact Analysis. February 2015; pp. 1-47 Pulmonary Rehabilitation for Postacute Exacerbations of Chronic Obstructive Pulmonary Disease (COPD): A Cost-Effectiveness and Budget Impact Analysis X XIE, M WANG, A SCHAINK (...) , M KRAHN FEBRUARY 2015 Pulmonary Rehabilitation for Postacute Exacerbations of Chronic Obstructive Pulmonary Disease (COPD): A Cost-Effectiveness and Budget Impact Analysis. February 2015; pp. 1-47 Pulmonary Rehabilitation for Postacute Exacerbations of Chronic Obstructive Pulmonary Disease (COPD): A Cost-Effectiveness and Budget Impact Analysis. February 2015; pp. 1-47 Pulmonary Rehabilitation for Postacute Exacerbations of Chronic Obstructive Pulmonary Disease (COPD): A Cost-Effectiveness

Health Quality Ontario2015

176. Hand-held Fourier transform infrared (FTIR) spectroscopy to diagnose and monitor COPD

Hand-held Fourier transform infrared (FTIR) spectroscopy to diagnose and monitor COPD Hand-held Fourier transform infrared (FTIR) spectroscopy to diagnose and monitor COPD Hand-held Fourier transform infrared (FTIR) spectroscopy to diagnose and monitor COPD NIHR HSRIC Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation NIHR HSRIC. Hand-held Fourier transform (...) infrared (FTIR) spectroscopy to diagnose and monitor COPD. Birmingham: NIHR Horizon Scanning Research&Intelligence Centre. Horizon Scanning Review. 2015 Authors' objectives The hand-held Fourier transform infrared (FTIR) spectroscopy device, developed by Glyconics Ltd., analyses the composition of sputum from patients with chronic obstructive pulmonary disease (COPD), to diagnose and monitor the disease. The device is intended to be used in the home by health professionals, as well as in primary

Health Technology Assessment (HTA) Database.2015

177. BuddyWOTCHT to monitor COPD

BuddyWOTCHT to monitor COPD BuddyWOTCH™ to monitor COPD BuddyWOTCH™ to monitor COPD NIHR HSRIC Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation NIHR HSRIC. BuddyWOTCH™ to monitor COPD. Birmingham: NIHR Horizon Scanning Research&Intelligence Centre. Horizon Scanning Review. 2015 Authors' objectives BuddyWOTCH™ is a smartwatch that can be worn all the time at home (...) to monitor the health of patients with chronic obstructive pulmonary disease (COPD). It has sensors that record walking, oxygen levels in the blood, temperature and heart rate. The developer says it can detect and warn the patient of a COPD 'flare-up', so that they can access treatments quicker. Final publication URL Indexing Status Subject indexing assigned by CRD MeSH Humans; Monitoring, Physiologic; Pulmonary Disease, Chronic Obstructive Language Published English Country of organisation England

Health Technology Assessment (HTA) Database.2015

178. Olodaterol (as hydrochloride) (Striverdi Respimat) - as a maintenance bronchodilator treatment in patients with chronic obstructive pulmonary disease (COPD)

Olodaterol (as hydrochloride) (Striverdi Respimat) - as a maintenance bronchodilator treatment in patients with chronic obstructive pulmonary disease (COPD) Final Appraisal Recommendation Advice No: 3614 – November 2014 Olodaterol (as hydrochloride) (Striverdi ® Respimat ® ? ) 2.5 microgram solution for inhalation Submission by Boehringer Ingelheim Ltd In reaching the above recommendation AWMSG has taken account of the appraisal documentation prepared by the AWMSG Secretariat (reference number (...) November 2014 Last reviewed June 2018 Recommendation of AWMSG Olodaterol (as hydrochloride) (Striverdi ® Respimat ® ? ) is recommended as an option for use within NHS Wales as a maintenance bronchodilator treatment in patients with chronic obstructive pulmonary disease (COPD). Statement of use: No part of this recommendation may be reproduced without the whole recommendation being quoted in full and cited as: All Wales Medicines Strategy Group. Final Appraisal Recommendation – 3614: Olodaterol

All Wales Medicines Strategy Group2015

179. Umeclidinium (Incruse) - as a maintenance bronchodilator treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease (COPD).

Umeclidinium (Incruse) - as a maintenance bronchodilator treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease (COPD).

Scottish Medicines Consortium2014

180. Indacaterol maleate, glycopyrronium bromide (Ultibro Breezhaler) - maintenance bronchodilator treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease (COPD).

Indacaterol maleate, glycopyrronium bromide (Ultibro Breezhaler) - maintenance bronchodilator treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease (COPD). Published 08 December 2014 Product Update: indacaterol maleate 143micrograms (equivalent to 110microgram indacaterol) with glycopyrronium bromide 63micrograms (equivalent to 50microgram glycopyrronium) inhalation powder hard capsules (Ultibro ® Breezhaler ® 85microgram/43microgram [delivered dose (...) Scotland. Indication under review: maintenance bronchodilator treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease (COPD). For patients in whom the combination of indacaterol maleate and glycopyrronium bromide is an appropriate choice of therapy, Ultibro ® Breezhaler ® provides the two ingredients in a single hard capsule at a lower cost than the individual components. Advice context: No part of this advice may be used without the whole of the advice being quoted

Scottish Medicines Consortium2014